- Home
- UGI vs ROIV Comparison
UGI vs ROIV Comparison
Compare UGI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UGI | ROIV |
|---|---|---|
| Founded | 1940 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UGI | ROIV |
|---|---|---|
| Price | $38.43 | $21.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $44.00 | $24.31 |
| AVG Volume (30 Days) | 2.6M | ★ 7.9M |
| Earning Date | 02-04-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | ★ 147.20 | N/A |
| EPS | ★ 3.09 | N/A |
| Revenue | ★ $7,287,000,000.00 | $20,329,000.00 |
| Revenue This Year | $27.27 | N/A |
| Revenue Next Year | $2.85 | $376.94 |
| P/E Ratio | $12.40 | ★ N/A |
| Revenue Growth | ★ 1.07 | N/A |
| 52 Week Low | $26.73 | $8.73 |
| 52 Week High | $39.59 | $23.47 |
Technical Indicators
Market Signals| Indicator | UGI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 67.94 | 58.99 |
| Support Level | $37.90 | $20.14 |
| Resistance Level | $38.51 | $23.47 |
| Average True Range (ATR) | 0.68 | 0.86 |
| MACD | -0.11 | 0.08 |
| Stochastic Oscillator | 59.09 | 54.42 |
Price Performance
Historical ComparisonAbout UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.